COVID-19 Stocks
Biotechnology and medical diagnostic entities in this cohort focus on the development of mRNA vaccines, antiviral therapeutics, and rapid lateral flow assay kits specifically designed to address infectious respiratory pathogens.
As of Oct 23, 2026, COVID-19 has 12 US-listed companies worth $105B combined. The median member moved -7.1% over the past week; NNVC led at +1.4% and VRAX trailed at -15.9%.
Companies in COVID-19
- MRNA – Moderna Inc, $79.9B
- BNTX – BioNTech SE, $22.9B
- NVAX – Novavax Inc, $1.9B
- ARCT – Arcturus Therapeutics Holdings Inc, $308M
- IVVD – Invivyd Inc., $182M
- VXRT – Vaxart Inc, $105M
- TVGN – Tevogen Bio Holdings Inc., $46M
- NNVC – NanoViricides Inc, $33.2M
- COCP – Cocrystal Pharma Inc, $20.8M
- TRAW – Traws Pharma Inc, $5.7M
- GOVX – GeoVax Labs Inc, $2.9M
- VRAX – Virax Biolabs Group Limited Ordinary Shares, $1.8M